Dr. Shi has led 7 research projects funded by the National Key Research and Development Program of China, National Natural Science Foundation of China, Tianjin Major Science and Technology Project for the Prevention and Control of Major Diseases, and the Innovative Team Program of the CAMS. He has published over 50 papers in high-impact journals, including The New England Journal of Medicine, Blood, Nature Communications, Cell Reports Medicine, Oncogene, Cancer Research, American Journal of Hematology and British Journal of Haematology. He also received two provincial-level scientific awards. As a physician scientist, Dr. Shi focuses on clinical and basic research in red blood cell diseases.
Research concentrates on three main areas:
• CRISPR-Cas9 gene editing and lentiviral gene therapy for transfusion-dependent beta-thalassemia.
• CAR T-cell therapy for refractory/relapsed autoimmune hemolytic anemia.
• Single-cell transcriptome analysis for the pathophysiological mechanisms of bone marrow failure and cellular ecology post hematopoietic reconstitution.
As Deputy Head of the Red Blood Cell Diseases Group of Hematology Committee of CMA, he established the Chinese Aplastic Anemia Collaborative Group to lead multicenter clinical studies, develop disease-specific databases, and standardize diagnosis and treatment across member hospitals nationwide. In stem cell and regenerative medicine, his team conducted 7 pioneering gene therapy studies for thalassemia and was the first to apply cell therapy to refractory/relapsed autoimmune hemolytic anemia, with research findings published in The New England Journal of Medicine. His work has contributed to advancing the clinical translation of innovative therapies in red blood cell diseases and shaping the evolving landscape of disease management and patient care.
MD, PhD, Internal Medicine, Peking Union Medical College, Beijing, China, 1998-2003
MB, Clinical Medicine, Tongji Medical University, Hubei, Wuhan, China, 1990-1995
Deputy Director, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (IHBDH, CAMS & PUMC), 2023- Present
Deputy director, National Clinical Research Center for Hematologic Diseases, 2020- Present
Director and Chief Physician, Red Blood Cell Diseases Center, IHBDH, 2023- Present
Director and Chief Physician, Regenerative Medicine Clinic Center, IHBDH, 2019- Present
Visiting Scholar, Hematology & Oncology Center, University of Illinois at Chicago, USA, 2006-2007
PRINCIPAL HONORS, AWARDS:
2022 Tianjin Natural Science Award
2000 Tianjin Scientific and Technological Progress Award
MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
2019- Present Member, Hematology Committee of Chinese Medical Association (CMA)
2019- Present Deputy Head, Red Blood Cell Diseases Group, Hematology Committee of CMA
2024- Present Standing Committee Member, Committee of the Hematology Branch of the Chinese Hospital Association
2025- Present Member, Committee of the Hematology Physicians Branch of the Chinese Medical Doctor Association
2020- Present Editorial Board Member, Chinese Journal of Hematology
SELECTED PUBLICATIONS:
1. Zhang L, Gao Z, Pan H, Li R, Fang L, Li W, Zhao J, Yu X, Kuang Z, Nie N, Li J, Huang J, Zhao X, Ge M, Zheng Y, Luo Y, Shi J*. The New England Journal of Medicine. 2025. (Accepted)
2. Gao Z, Pan H, Zhang L, Li W, Li R, Zhao J, Luo Y, Lian Y, Yu X, Kuang Z, Nie N, Li J, Huang J, Zhao X, Li Y, Fang L, Ge M, Zheng Y, Shi J*. Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia. Blood. 2025 May.(Epub ahead of print)
3. Zhang L, Qiu C, Li R, Shen Y, Tian L, Chang H, Liang Q, Pan H, Gao Z, Li W, Zhao J, Fang L, Yu X, Xu J, Kuang Z, Yuan W*, Chu Y*, Shi J*. KLRG1 re-define a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T-cell large granular lymphocytic leukemia. Cell Reports Medicine. 2025 April; 6(4), 102036–102036.
4. Mao J, Zhao J, Pan H, Gao Z, Zhang L, Li W, Fang L, Liu C, Su P, Wang H*, Zhou J*, Shi J*. Application of platelet transcriptomics for assessing treatment effectiveness and predicting long-term platelet counts recovery in aplastic anemia. Journal of Thrombosis and Haemostasis. 2024 Nov; 23(2), 692–703.
5. Wang B, Shi D, Yang S, Lian Y, Li H, Cao M, He Y, Zhang L, Qiu C, Liu T, Wen W, Ma Y, Shi L, Cheng T, Shi L, Yuan W*, Chu Y*, Shi J*. Mitochondrial tRNA pseudouridylation governs erythropoiesis. Blood. 2024 Aug 8; 144(6): 657-671.
6. Shi D, Wang B, Li H, Lian Y, Ma Q, Liu T, Cao M, Ma Y, Shi L, Yuan W*, Shi J*, Chu Y*. Pseudouridine synthase 1 regulates erythropoiesis via transfer RNAs pseudouridylation and cytoplasmic translation. iScience. 2024; 27(3): 109265.
7. Zhang L, Zhao J, Li R, Pan H, Gao Z, Li W, Fang L, Shi J*. Low risk of relapse in aplastic anemia patients after SARS-CoV-2 omicron infection: A prospective NICHE cohort. Am J Hematol. 2023 Jul; 98(10): E272-E275.
8. Li Y, He M, Zhang W, Liu W, Xu H, Yang M, Zhang H, Liang H, Li W, Wu Z, Fu W, Xu S, Liu X, Fan S, Zhou L, Wang C, Zhang L, Li Y, Gu J, Yin J, Zhang Y, Xia Y, Mao X, Cheng T*, Shi J*, Du Y*, Gao Y*. Expansion of human megakaryocyte-biased hematopoietic stem cells by biomimetic Microniche. Nat Commun. 2023; 14(1): 2207–2207.
9. Zhu C, Lian Y, Wang C, Wu P, Li X, Gao Y, Fan S, Ai L, Fang L, Pan H, Cheng T*, Shi J*, Zhu P*. Single-cell transcriptomics dissects hematopoietic cell destruction and T cell engagement in aplastic anemia. Blood. 2021 Jul; 138(1): 23-33.
10. Chu Y*, Chen Y, Guo H, Li M, Wang B, Shi D, Cheng X, Guan J, Wang X, Xue C, Cheng T, Shi J*, Yuan W*. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia. Oncogene. 2020; 39(50): 7239-7252.